Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Does Cinnamon Help with Weight Loss?

How Does Semaglutide Work to Lose Weight?

Circadian Rhythm and Weight Loss

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

How Oral GLP-1 Drugs Work For Weight Loss

Wegovy: A Breakthrough in Weight Loss?

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Vegetarian Diets for Weight Loss

Mental Health Disorders, Weight Gain, and Exercise

Cachexia and Cancer

See more featured articles »

Cachexia / Wasting Syndrome

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Semaglutide and Weight Loss in Menopause

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Unexplained Weight Loss: When It Might Signal a Health Problem

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

The Natural Molecule That Could Rival Ozempic

Military Diet: Health Risks

Weight Loss After Bariatric Surgery

Latest Weight Loss News and Research

New compound shows promise in protecting the liver from damage after small bowel surgery

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Novel gene regulation therapy passes key clinical milestone

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective.

4 Mar 2026

Mapping the year-one weight trajectory after stopping GLP-1s

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge.

4 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

Study uncovers a biological cause for persistent taste loss after COVID-19

Some individuals have experienced a loss of taste long after a COVID-19 infection has subsided. Researchers from the Swedish University of Agricultural Sciences, Uppsala University and the University of Colorado have now shown that this may be due to a disruption in taste cells that would otherwise give rise to experiences of sweet, bitter or umami.

4 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Study shows weighted vests prevent metabolic slowdown during weight loss

It's encouraging news for people trying to lose weight safely, especially older adults who want to drop pounds without losing bone or muscle mass.

3 Mar 2026

Experts call for rapid improvements in diagnosis, treatment of bile duct cancer

The international group of experts, including Professor John Bridgewater (UCL Cancer Institute), is calling for rapid improvements in diagnosis, treatment and research for cholangiocarcinoma, also known as bile duct cancer.

2 Mar 2026

The surprising neurological benefits of GLP-1s

For people with chronic migraine, taking glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, for other conditions such as diabetes and weight loss, was associated with fewer emergency department visits and hospitalizations overall, and with less need for medications used to stop and prevent migraine attacks, according to a preliminary study released March 1, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

2 Mar 2026

To avoid care disruptions, know when the clock runs out on your prior authorization

A woman with multiple sclerosis wanted to be able to walk up the stairs at home without losing her balance.

27 Feb 2026

Targeting glutamine metabolism offers new hope for synovial sarcoma treatment

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults.

26 Feb 2026

Untreated sleep apnea may cost the UK and US billions annually

Untreated obstructive sleep apnea may be costing the UK and US economies billions of pounds/dollars in lost productivity every year, with a considerable proportion of working age adults experiencing symptoms indicative of the breathing disorder, suggests an analysis published online in the journal Thorax.

24 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Transforming obese fat cells into energy burners

Ordinary fat cells in obese animals can be induced to burn energy stores, generating substantial heat, according to a preclinical study by Weill Cornell Medicine investigators.

23 Feb 2026

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

Higher intake of ultra-processed foods in adults with obesity was associated with disordered eating symptoms, poorer diet quality, and lower protein intake. The cross-sectional findings suggest dietary processing level may influence eating behaviour patterns relevant to obesity management, though causality cannot be inferred.

23 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Intermittent calorie restriction proves as effective as daily calorie cuts for type 2 diabetes

A post-hoc analysis of two clinical trials compared continuous calorie restriction with early time-restricted eating in adults with type 2 diabetes and overweight or obesity over three months. Both approaches improved weight, body composition, and metabolic health, with no clear superiority except for lower dropout with intermittent restriction.

18 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026